ROS1 and lung carcinoma: Currently, ROS1 inhibitors are widely used to treat lung cancer patients with ROS1 mutations, and there are also phase I and phase II clinical trials for ROS1 inhibitors to treat patients with other advanced or metastatic solid tumors.